Dapsone 100mg tablets
Requires a prescription from a doctor or prescriber
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Dapsone
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Dapsone
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Dapsone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
15 branded products available
MHRA licensed products
View all licensed products for Dapsone on the MHRA register
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
Dapsone 100mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
50 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(6)
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 30 · Randomised trials: 8 · 1993–2026
Showing the 50 most relevant studies, sorted by most relevant.
Omar Azuara-Antonio, Mario Isidoro Ortiz, Karla Daniela Jiménez-Oliver, et al.
São Paulo Medical Journal, 2024
Khan I, Qasim SA, Rath S, et al.
2025
- Purpura, Thrombocytopenic, Idiopathic
- Dapsone
W. Tangamornsuksan, MANUPAT LOHITNAVY
JAMA Dermatology, 2018
G. Wozel, C. Blasum
Archives of Dermatological Research, 2013
Rsjb Rana D, Shah M, Baral S, et al.
2026
- Leprosy
- Drug Hypersensitivity
- Dapsone
BackgroundDapsone Hypersensitivity Syndrome (DHS) is a serious debilitating condition which can develop after 2-8 weeks of dapsone treatment in varying proportions between genetically diverse populations. Approximately 10% of the affected individuals die, and DHS patients often spend weeks to months in the hospital, which impacts health and psychological morbidity and household financial burden. In recent years, a human leukocyte antigen, HLA-B*13:01, has been consistently associated with up to 85% of DHS cases across international population studies; however, the necessity of next generation sequencing (NGS) severely limits clinical applications in low resource contexts.Methodology/principal findingTo investigate HLA-B*13:01 associations with DHS among Nepalese leprosy cases, retrospective and active DHS cases and dapsone-tolerant controls treated at least for 3 months with multi-drug therapy (MDT) were sampled and screened by HLA-B*13:01 qPCR. In the present study we enrolled 34 DHS cases and 82 dapsone tolerant controls and found that the association is maintained in a multi-ethnic Nepali population with an Odds Ratio of 50.1 (95% CI: 15.0-166.6). A previously validated qPCR-based commercial kit was used in the study, and we revalidated the methodology (23 negative and 35 positives by commercial qPCR) using Next Generation sequencing (NGS) method and found a concordance rate of 98.3%. We meta-analyzed all eligible HLA-B*13:01 and DHS association studies and found a summary Odds Ratio of 61.86 (95% CI 32.60 - 117.4). As 23.5% of the DHS cases were HLA-B*13:01 negative in our study, further analyses of the HLA-B*13:01 positive and negative study participants revealed that HLA-B*13:01 positive DHS cases were significantly younger than HLA-B*13:01 negative DHS cases (35.5 years vs. 66 years, p = 0.0018). The positive predictive value of the HLA test in the Nepalese population was ~ 24.ConclusionThe study validates the association between HLA-B*13:01 and DHS in Nepalese leprosy population. Inclusion of a genetic screening test before starting MDT could potentially prevent significant proportion of DHS occurring in leprosy cases, especially in South Asian and Southeast countries.
Abstract licence: CC BY
Xuesong Wang, Zhenzhen Wang, Lulu Sun, et al.
Annals of palliative medicine, 2022
Keumwha Lee, Sung Hwi Hong, Jinhae Jun, et al.
Clinical and Experimental Pediatrics, 2019
H. Park, Jungwon Park, Sae-Hoon Kim, et al.
Expert Opinion on Drug Safety, 2020
Ziwei Wu, Chen Wang, Zhenzhen Wang, et al.
Journal of global antimicrobial resistance, 2022
Sydney E. Liang, Rachel K. Hoffmann, E. Peterson, et al.
JAMA Dermatology, 2019
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
28 hours
Mechanism
Dapsone acts against bacteria and protozoa in the same way as sulphonamides, tha…
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
70 to 80%
Half-life
28 hours
Protein binding
70 to 90%
Metabolism
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 723 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC J04BA50
ATC J04BA51
ATC D10AX05
ATC J04BA02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Dapsone
Additional database identifiers
Drugs Product Database (DPD)
8120
ChemSpider
2849
BindingDB
50029764
ZINC
ZINC000000006310
GenBank Gene Database
U15180
GenBank Protein Database
699152
UniProt Accession
DHPS2_MYCLE
GenBank Gene Database
AB028658
GenBank Protein Database
5832717
UniProt Accession
DHPS1_MYCLE
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7218
GenAtlas
MPO
GeneCards
MPO
GenBank Gene Database
J02694
GenBank Protein Database
189040
Guide to Pharmacology
2789
UniProt Accession
PERM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2620
GeneCards
CYP2C18
GenBank Gene Database
M61853
Guide to Pharmacology
1327
UniProt Accession
CP2CI_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2631
GeneCards
CYP2E1
GenBank Gene Database
J02625
GenBank Protein Database
181360
Guide to Pharmacology
1330
UniProt Accession
CP2E1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3771
GeneCards
FMO3
GenBank Gene Database
M83772
GenBank Protein Database
188631
UniProt Accession
FMO3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9604
GenAtlas
PTGS1
GeneCards
PTGS1
GenBank Gene Database
M31822
GenBank Protein Database
387018
Guide to Pharmacology
1375
UniProt Accession
PGH1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9605
GenAtlas
PTGS2
GeneCards
PTGS2
GenBank Gene Database
L15326
GenBank Protein Database
291988
Guide to Pharmacology
1376
UniProt Accession
PGH2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2622
GenAtlas
CYP2C8
GeneCards
CYP2C8
GenBank Gene Database
M17397
Guide to Pharmacology
1325
UniProt Accession
CP2C8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7646
GeneCards
NAT2
GenBank Gene Database
D90040
GenBank Protein Database
219412
UniProt Accession
ARY2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2640
GeneCards
CYP3A7
GenBank Gene Database
D00408
GenBank Protein Database
220149
UniProt Accession
CP3A7_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72